This pilot clinical trial studies stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
PRIMARY OBJECTIVES: I. Assess the impact of stereotactic body radiation therapy (SBRT) on the immune system in patients with metastatic renal cell carcinoma (RCC). SECONDARY OBJECTIVES: I. Assess changes in immune parameters prior to radiation, post radiation and post nephrectomy. TERTIARY OBJECTIVES: I. Assess surgical parameters for partial or radical nephrectomy post SBRT. OUTLINE: Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29. After completion of study treatment, patients are followed up at 30 days.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Undergo SBRT
Undergo partial or radical nephrectomy
Correlative studies
Roswell Park Cancer Institute
Buffalo, New York, United States
Feasibility of conducting a partial nephrectomy in patients with no prior stereotactic radiation for kidney cancer
Time frame: Up to 30 days post-treatment
Toxicity analysis assessed by the CTEP Version 4 of the NCI Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: Up to 30 days post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.